Why Intellia Therapeutics Stock Plummeted by 20% Today

Thursday was hardly a good day to be a shareholder of Intellia Therapeutics (NASDAQ: NTLA). After the biotech delivered some news from the lab and witnessed one analyst's negative reaction to it, the company's share price closed more than 20% lower.Intellia, which is a clinical-stage biotech developing medications using cutting-edge, genome-editing technology, delivered its latest news that morning. The company unveiled the results from a phase 2 trial of its NTLA-2002, which targets hereditary angioedema (HAE), a swelling disorder. The 27-patients study saw the treatment reduce monthly angioedema attack rates by 86% to 81%. In a group of 11 patients using a higher dose of the drug, eight had a complete response to treatment, i.e., they experienced no attacks for up-to eight months after dosing.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool